Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2018-07-12 Share Issue/Capital Cha…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly states "Share capital increase registered" and details a completed private placement involving the issuance of new shares, resulting in a change to the total registered share capital (NOK 1,539,592.10 divided on 15,395,921 shares). This directly relates to a change in the company's capital structure via new share issuance. This aligns perfectly with the definition for Share Issue/Capital Change (SHA). The document length is very short (888 chars), but the content is a definitive statement of a capital change, not just an announcement of a report, making SHA the most accurate classification over RPA/RNS.
2018-07-12 English
Notice of extraordinary general meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'NOTICE OF EXTRAORDINARY GENERAL MEETING' and details the date, time, location, and proposed agenda for a shareholder meeting. It includes registration forms and proxy authorization forms for attendees. This content directly relates to the formal process and materials surrounding a general meeting, fitting the definition of 'AGM Information' (AGM-R), even though it is an 'Extraordinary' meeting, as it concerns shareholder assembly and voting.
2018-07-02 English
Notice of extraordinary general meeting
AGM Information Classification · 98% confidence The document is explicitly titled 'Notice of extraordinary general meeting' and details the date, time, location, and proposed agenda for this meeting. The agenda includes items like 'ELECTION OF BOARD MEMBER'. This content directly relates to the formal process and materials surrounding a shareholder meeting, specifically an Extraordinary General Meeting (EGM). While the document is a notice, it is not a general regulatory filing (RNS) or a proxy solicitation (PSI) which typically solicits votes for a scheduled AGM/EGM. Since the document is the notice itself for a meeting that involves shareholder voting and board elections, and given the available codes, it most closely aligns with the context of an Annual General Meeting (AGM-R) or a related meeting notice, even though it specifies 'extraordinary'. In the absence of a specific EGM code, AGM-R is the closest fit for formal meeting documentation, although it is a notice rather than the final results (DVA) or the proxy materials (PSI). However, since it is the formal notice calling the meeting, and it mentions that related proposals are available on the website (suggesting proxy materials might follow or be separate), it is best classified as related to the general meeting process. Given the options, and recognizing that this is the official call to the meeting, it is highly related to AGM proceedings.
2018-07-02 English
GENTIAN ACHIEVES PROOF OF CONCEPT ON FECAL PANCREATIC ELASTASE
Regulatory Filings Classification · 95% confidence The document announces a significant business development: Gentian Diagnostics achieving proof of concept for a new product (turbidimetric measurement of Fecal Pancreatic Elastase - fPELA) and signing an exclusive cooperation agreement for its development and distribution. This is a material event announcement concerning product development and strategic partnerships, not a routine financial filing like a 10-K, ER, or IR. It fits best under general regulatory announcements or corporate updates that don't fit the highly specific categories. Since it is a specific announcement of a corporate event/development, and not a standard financial report, it is classified as a Regulatory Filing (RNS) as a general announcement category, although it shares characteristics with an 'IP' or 'ER' in terms of content focus, the structure is that of a press release/announcement.
2018-06-22 English
GENTIAN ACHIEVES PROOF OF CONCEPT ON FECAL PANCREATIC ELASTASE
Regulatory Filings Classification · 100% confidence The document is a short announcement dated June 22, 2018, stating that Gentian Diagnostics has achieved 'proof of concept' for a new diagnostic test (Fecal Pancreatic Elastase). It details a collaboration with BÜHLMANN Laboratories AG and mentions future market potential. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or a management discussion (MDA). It is an announcement regarding a specific business development, partnership, and product pipeline progress. Since it doesn't fit the specific categories like Capital/Financing (CAP), M&A (TAR), or Director's Dealing (DIRS), it falls best under the general Regulatory Filings category (RNS) as a miscellaneous corporate announcement, although it is more specific than a typical RNS filing. Given the options, RNS serves as the best catch-all for significant, non-standard corporate news that isn't explicitly covered elsewhere. It is not a Report Publication Announcement (RPA) because it is announcing a technical achievement, not the publication of a formal financial report.
2018-06-22 English
Flaggemelding Gentian Diagnostics AS.
Major Shareholding Notification Classification · 98% confidence The document is titled "Flaggemelding" (Flagging Announcement) and details a change in share ownership percentage (from 5.35% to 4.86%) following a directed share issue ('rettede emisjonen'). This directly relates to changes in significant share ownership thresholds. According to the definitions, 'Major Shareholding Notification' (MRQ) covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document is very short, but its content is a direct notification of a change in holding, not just an announcement that a report is available. Therefore, MRQ is the most appropriate classification.
2018-06-15 Norwegian

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.